Last $20.86 USD
Change Today -0.28 / -1.32%
Volume 46.3K
TKPYY On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 2:20 PM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutic-sp adr (TKPYY) Snapshot

Open
$21.03
Previous Close
$21.14
Day High
$21.03
Day Low
$20.86
52 Week High
12/11/13 - $25.09
52 Week Low
10/17/14 - $20.47
Market Cap
32.9B
Average Volume 10 Days
45.0K
EPS TTM
--
Shares Outstanding
1.6B
EX-Date
09/25/14
P/E TM
--
Dividend
$0.89
Dividend Yield
2.13%
Current Stock Chart for TAKEDA PHARMACEUTIC-SP ADR (TKPYY)

Related News

No related news articles were found.

takeda pharmaceutic-sp adr (TKPYY) Details

Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacturing, marketing, sale, and import/export of pharmaceutical drugs worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, respiratory and immunology, oncology, central nervous system, general medicine, vaccines, and consumer healthcare drugs and quasi-drugs. The company has strategic partnership with BioMotiv, LLC. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

31,225 Employees
Last Reported Date: 06/27/14
Founded in 1781

takeda pharmaceutic-sp adr (TKPYY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

takeda pharmaceutic-sp adr (TKPYY) Key Developments

GE Healthcare and Takeda Partner to Develop Liver Disease Therapeutics

GE Healthcare and Takeda Pharmaceutical Company have entered into an alliance agreement for R&D in the field of hepatic fibrosis, a factor involved in the diagnosis and treatment of liver diseases. According to the alliance agreement, GE Healthcare will provide Takeda with its diagnostic imaging technology for use to generate a liver stiffness map as part of the R&D work Takeda is conducting on liver diseases. By optimizing the strengths of both companies in the alliance, the collaborative effort aims to help develop therapeutic drugs as well as new diagnostic technologies for liver diseases.

Takeda Pharmaceutical Company Limited Announces Abstracts of Interest from Studies on VELCADE, ADCETRIS and the Investigational Oral Proteasome Inhibitor, Ixazomib

Takeda Pharmaceutical Company Limited announced that abstracts of interest from studies on VELCADE, ADCETRIS and the investigational oral proteasome inhibitor, ixazomib, are among those that have been accepted for presentation at this year's American Society of Hematology annual meeting to be held December 6 to December 9, 2014 in San Francisco, California. Data selected for presentation include results from the Phase 3 AETHERA clinical trial evaluating the potential treatment of brentuximab vedotin, a CD30-targeted antibody drug conjugate, as consolidation therapy immediately following an autologous stem cell transplantation in patients with Hodgkin lymphoma at high risk of relapse or progression. Other presentations will feature long-term survival data for ADCETRIS in relapsed or refractory systemic Anaplastic Large Cell Lymphoma and results from a Phase 2 study examining long-term maintenance therapy with oral proteasome inhibitor ixazomib for patients with previously untreated multiple myeloma. Takeda's abstracts of interest at ASH 2014 include: The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma. Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients with Previously Untreated Multiple Myeloma: Phase 2 study results.

Takeda Pharmaceutical Company Limited Presents at BIO-Europe 2014, Nov-03-2014 through Nov-05-2014

Takeda Pharmaceutical Company Limited Presents at BIO-Europe 2014, Nov-03-2014 through Nov-05-2014. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany. Presentation Date & Speakers: Nov-03-2014, Michael Martin, Senior Director, Global Licensing and Business Development, Natalie Mirutenko, Senior Director, Search & Evaluation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TKPYY:US $20.86 USD -0.28

TKPYY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.51 USD +0.26
Astellas Pharma Inc ¥1,707 JPY +9.50
Baxter International Inc $73.00 USD +0.60
Becton Dickinson and Co $140.33 USD -0.93
Shire PLC 4,557 GBp -21.00
View Industry Companies
 

Industry Analysis

TKPYY

Industry Average

Valuation TKPYY Industry Range
Price/Earnings 35.4x
Price/Sales 2.1x
Price/Book 1.5x
Price/Cash Flow 11.8x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTIC-SP ADR, please visit www.takeda.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.